Abstract
Immune checkpoint inhibitors, such as the programmed cell death protein 1 (PD-1) inhibitors, are gaining popularity in the treatment of several types of cancer, and function by stimulating the immune system’s antitumor activity. Immune-related adverse events are common following the use of immune checkpoint inhibitors with rash being the most frequent complaint. Herein, we present the case of a 67-year-old woman with a history of plaque psoriasis and metastatic squamous cell carcinoma of the lung who presented with widespread well-defined erythematous scaly plaques following a dose increase of pembrolizumab (a PD-1 inhibitor).While cutaneous adverse events are common with the use of PD-1 inhibitors, they most frequently manifest as morbilliform eruptions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
